Harpoon Therapeutics, Inc.
MESOTHELIN BINDING PROTEINS

Abstract:

Disclosed herein are MSLN binding proteins with improved binding affinities and improved ability to mediate T cell dependent killing of cancer cells expressing mesothelin. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are further provided.